Canine influenza virus vaccines TruCan Ultra by Elanco and Nobivac NXT by Merck, were introduced in 2025. Each of these elicit significant disease-sparing responses in experimentally infected dogs, as measured by reduction in CIV-induced pulmonary lesions, writes John Ellis DVM, PhD, DACVP, DACVM. His article focuses on new additions to the prophylactic armamentarium for CIV, their mechanisms of action, efficacy data and recommendations for use.
Source: Today’s Veterinary Practice, February 12, 2026. Link.
Experimental CIV infections have shown that both new vaccines confer similar efficacy. Use of CIV vaccines should be based primarily on assessment of anticipated risk for exposure to circulating CIVs. Other risk considerations are based on breed predilection or comorbidities.” – John Ellis DVM, PhD, DACVP, DACVM
Leave a Reply